0001209191-21-034718.txt : 20210520
0001209191-21-034718.hdr.sgml : 20210520
20210520205009
ACCESSION NUMBER: 0001209191-21-034718
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210518
FILED AS OF DATE: 20210520
DATE AS OF CHANGE: 20210520
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Xie Jian
CENTRAL INDEX KEY: 0001819718
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37894
FILM NUMBER: 21946325
MAIL ADDRESS:
STREET 1: C/O FULGENT GENETICS, INC.
STREET 2: 4978 SANTA ANITA AVE., SUITE 205
CITY: TEMPLE CITY
STATE: CA
ZIP: 91780
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Fulgent Genetics, Inc.
CENTRAL INDEX KEY: 0001674930
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071]
IRS NUMBER: 812621304
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4978 SANTA ANITA AVENUE, SUITE 205
CITY: TEMPLE CITY
STATE: CA
ZIP: 91780
BUSINESS PHONE: 626-350-0537
MAIL ADDRESS:
STREET 1: 4978 SANTA ANITA AVENUE, SUITE 205
CITY: TEMPLE CITY
STATE: CA
ZIP: 91780
FORMER COMPANY:
FORMER CONFORMED NAME: Fulgent Diagnostics, Inc.
DATE OF NAME CHANGE: 20160517
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-05-18
0
0001674930
Fulgent Genetics, Inc.
FLGT
0001819718
Xie Jian
C/O FULGENT GENETICS, INC.
4978 SANTA ANITA AVE., STE 205
TEMPLE CITY
CA
91780
0
1
0
0
Chief Operating Officer
Common Stock
2021-05-18
4
S
0
931
70.7102
D
341041
D
Common Stock
2021-05-20
4
S
0
1000
74.48
D
340041
D
The shares were sold by the reporting person to generate proceeds used to satisfy the tax withholding obligation that arose upon the vesting of certain restricted stock units granted to the reporting person on November 1, 2019.
The shares were sold in multiple transactions at prices ranging from $69.61 to $71.05, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
/s/ Paul Kim as Attorney-in-Fact
2021-05-20